Skip NavigationSkip to Content
Return Return to Search Results

Serum insulin-like growth factor 1: Tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men

  1. Author:
    Woodson, K.
    Tangrea, J. A.
    Pollak, M.
    Copeland, T. D.
    Taylor, P. R.
    Virtamo, J.
    Albanes, D.

  2. Author Address

    NCI, Canc Prevent Studies Branch, Canc Res Ctr, 6116 Execut Blvd MSC 8314, Bethesda, MD 20892 USA NCI, Canc Prevent Studies Branch, Canc Res Ctr, Bethesda, MD 20892 USA NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA McGill Univ, Jewish Gen Hosp, Canc Prevent Res Unit, Dept Med, Montreal, PQ H3T 1E2, Canada McGill Univ, Jewish Gen Hosp, Dept Oncol, Lady Davis Res Inst, Montreal, PQ H3T 1E2, Canada NCI, Basic Res Lab, Canc Res Ctr, Frederick, MD 21701 USA Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Helsinki, Finland Woodson K NCI, Canc Prevent Studies Branch, Canc Res Ctr, 6116 Execut Blvd MSC 8314, Bethesda, MD 20892 USA
    1. Year: 2003
  2. Journal: Cancer Research
    1. 63
    2. 14
    3. Pages: 3991-3994
  4. Type of Article: Article
  1. Abstract:

    Recent epidemiological studies suggest an association between higher blood levels of insulin-like growth factor I (IGF-I) and increased risk of prostate cancer. We evaluated the association between prediagnostic levels of IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) and prostate cancer risk in a nested case-control study within the Alpha-Tocopherol, Beta- Carotene Cancer Prevention Study. Within the same cohort (using different cases and controls who had sequential serum samples available) we also examined changes in serum IGF-I and IGFBP-3 levels over time by case status. The risk association study included incident prostate cancer cases (n=100) diagnosed at least 5 years after baseline blood draw (range, 5-12 years; median 9 years) and frequency-matched (4:1) controls. The sequential serum study included all of the prostate cancer cases (n=21) with prediagnostic (2-3 years before diagnosis) and diagnostic serum available, and pair-matched controls (1:1). An ELISA was used to quantitate serum levels of IGF-I and IGFBP-3 for both studies. The association between IGF-I or IGFBP-3 and prostate cancer risk was assessed using conditional logistic regression, and paired t tests were used to evaluate case-control differences in change in serum analytes over time. We found no significant association between either IGF-I or IGFBP-3 and prostate cancer risk. In a multivariate analysis, we observed an odds ratio of 0.52 (95% confidence interval, 0.23-1.16) for the fourth versus the first quartile of serum IGF-I. Serum IGF-I, but not IGFBP-3, increased significantly over time in cases (18% increase) but not controls (4% decrease; P=0.02). In contrast to previous reports, we found no evidence to support a causal association between serum IGF-I or IGFBP-3 and the risk of prostate cancer. It is possible that serum IGF-I may be serving as a tumor marker rather than an etiologic factor in prostate cancer.

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel